470482-41-8

Usage

Chemical Properties

White powder

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1398113-32-0 2-tert-butyl 2-methyl (2S)-trifluoromethyl-3-pyrrolin-1,2-dicarboxylate 
• 470482-39-4 (S)-tert-butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-(trifluoromethyl)-2,3-dihydro-1H-pyrrole-1-carboxylate 
• 470482-36-1 (2S)-1-tert-butyl 2-methyl 4-hydroxy-4-(trifluoromethyl)pyrrolidine-1,2-dicarboxylate 
• 470482-42-9 (S)-tert-butyl 2-(hydroxymethyl)-4-(trifluoromethyl)-2,3-dihydro-1H-pyrrole-1-carboxylate 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 474417-76-0 benzyl (2S,4S)-N-tert-butoxycarbonyl-4-hydroxy-4-trifluoromethylprolinate 
• 51-35-4 4R-4-hydroxyproline 
• 154456-97-0 2-benzyl 1-(tert-butyl) (S)-4-oxopyrrolidine-1,2-dicarboxylate 
• 89813-47-8 N-(tert-butoxycarbonyl)-(2S,4R)-4-hydroxyproline benzyl ester 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 474417-77-1 2-benzyl 1-(tert-butyl) (S)-4-(trifluoromethyl)-2.5-dihydro-1H-pyrrole-1.2-dicarboxylate 

Downstream Products

• 1283142-69-7 2-((2S,4S)-1-(4-(3-Chloro-2-methylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic acid trifluoroacetic acid salt 
• 1283146-26-8 2-((2S,4S)-1-(4-(3-chloro-2-methylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile 
• 1283146-25-7 ((2S,4S)-1-(4-(3-chloro-2-methylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol 
• 1283142-67-5 2-((2S,4S)-1-(4-(2,3-dimethylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic acid trifluoroacetic acid salt 
• 1283146-23-5 2-((2S,4S)-1-(4-(2,3-dimethylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile 
• 1283146-22-4 ((2S,4S)-1-(4-(2,3-dimethylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol 
• 1283142-96-0 2-((2S,4S)-1-(4-(2-(trifluoromethoxy)phenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic acid trifluoroacetic acid salt 
• 1283146-52-0 2-((2S,4S)-1-(4-(2-(trifluoromethoxy)phenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile 
• 1283146-51-9 ((2S,4S)-1-(4-(2-(trifluoromethoxy)phenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol 
• 1283142-79-9 2-((2S,4S)-1-(4-(2,6-dimethylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic acid trifluoroacetic acid salt 
• 1283146-34-8 2-((2S,4S)-1-(4-(2,6-dimethylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile 
• 1283142-77-7 2-((2S,4S)-1-(4-(4-methoxy-2-methylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic acid trifluoroacetic acid salt 
• 1283146-33-7 2-((2S,4S)-1-(4-(4-methoxy-2-methylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile 
• 1283142-75-5 2-((2S,4S)-1-(4-(4-(benzyloxy)-2-methylphenoxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic acid trifluoroacetic acid salt 

Relevant academic research and scientific papers

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

γ-(S)-Trifluoromethyl proline: Evaluation as a structural substitute of proline for solid state 19F-NMR peptide studies

γ-(4S)-Trifluoromethyl proline was synthesised according to a modified literature protocol with improved yield on a multigram scale. Conformational properties of the amide bond formed by the amino acid were characterised using N-acetyl methyl ester model. The amide populations (s-trans vs. s-cis) and thermodynamic parameters of the isomerization were found to be similar to the corresponding values for intact proline. Therefore, the γ-trifluoromethyl proline was suggested as a structurally low-disturbing proline substitution in peptides for their structural studies by 19F-NMR. Indeed, the exchange of native proline for γ-trifluoromethyl proline in the peptide antibiotic gramicidin S was shown to preserve the overall amphipathic peptide structure. The utility of the amino acid as a selective 19F-NMR label was demonstrated by observing the re-alignment of the labelled gramicidin S in oriented lipid bilayers. This journal is

Practical synthesis of Boc-protected cis-4-trifluoromethyl and cis-4-difluoromethyl-L- prolines

A short, efficient, and diastereomerically pure synthesis of N-Boc-cis-4-trifluoromethyl-L-proline (7) and N-Boc-cis-4-difluoromethyl-L-proline (9) from N-Boc-4-oxo- L-proline (4) is described. The reaction of 4 with Me3SiCF3 and the conversion of the carbonyl group of 4 into the difluoromethylene group are the key steps for the synthesis of 7 and 9, respectively.

Stereoselective synthesis of Boc-protected cis and trans-4-trifluoromethylprolines by asymmetric hydrogenation reactions

Stereocontrolled synthesis of cis and trans-substituted prolines by a divergent approach, leads to the preparation of cis-(4S)- and trans-(4R)-trifluoromethyl-Lproline from hydroxyproline. The key pyrroline intermediates were subjected to hydrogenation (s